Why the vibes are different this year for JPM26

JPM week, the “Super Bowl of biotech” as some call it, is a yearly tradition for many in the industry (and those who cover it). The conference is unique in that often more action happens beyond the walls of the Westin St. Francis than happens within them. But without fail, companies merge or get acquired, deals get done, and people regret not bringing an umbrella or packing more comfortable shoes.  One thing that’s different, from last year anyway, is the mood going into the conference. In this week’s STATus Report, host Alex Hogan chats with STAT reporters Allison DeAngelis and Damian Garde about what they’ll be keeping an eye out for at JPM 2026, and why the vibes have shifted. 0:00 Intro 1:25 Any M&A rumors? 3:38 China's emergence in the biopharma space 4:46 a vibe shift afoot? 6:39 new CEOs this year 7:08 Anything else to look out for? 7:56 Outro/STAT's JPM co-working space More from STAT: Become a subscriber: https://www.statnews.com/stat-plus/ Watch Full Episodes: https://www.youtube.com/@Statnews Newsletters: https://www.statnews.com/signup/ STAT events: https://www.statnews.com/stat-events/ Facebook: https://www.facebook.com/statnews Twitter: https://twitter.com/statnews Instagram: https://www.instagram.com/statnews/ Flipboard: rb.gy/3xnsxr STAT Reports: https://rb.gy/rexfwj STAT eBooks: https://rb.gy/eme3h5 ABOUT STAT: Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health.